Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Vaccines | 4 | 2016 | 106 | 1.080 |
Why?
|
| Papillomavirus Infections | 4 | 2016 | 397 | 0.860 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2016 | 35 | 0.600 |
Why?
|
| Whooping Cough | 1 | 2016 | 61 | 0.480 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 87 | 0.470 |
Why?
|
| Postpartum Period | 2 | 2016 | 229 | 0.460 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2016 | 475 | 0.450 |
Why?
|
| Professional Competence | 1 | 2015 | 98 | 0.430 |
Why?
|
| Health Personnel | 2 | 2016 | 541 | 0.410 |
Why?
|
| Child Abuse | 3 | 2022 | 203 | 0.410 |
Why?
|
| Vaccination | 2 | 2020 | 1015 | 0.360 |
Why?
|
| Haemophilus Vaccines | 3 | 2017 | 32 | 0.360 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 486 | 0.350 |
Why?
|
| Education, Medical | 1 | 2015 | 302 | 0.350 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2017 | 12 | 0.250 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2017 | 16 | 0.250 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2025 | 10 | 0.240 |
Why?
|
| Tetanus Toxoid | 2 | 2014 | 50 | 0.230 |
Why?
|
| Meningococcal Vaccines | 2 | 2014 | 30 | 0.220 |
Why?
|
| Diffuse Axonal Injury | 1 | 2022 | 10 | 0.190 |
Why?
|
| Spinal Injuries | 1 | 2022 | 32 | 0.190 |
Why?
|
| Craniocerebral Trauma | 1 | 2022 | 143 | 0.170 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2020 | 14 | 0.170 |
Why?
|
| Immunization Schedule | 2 | 2017 | 105 | 0.150 |
Why?
|
| Texas | 3 | 2016 | 3713 | 0.150 |
Why?
|
| Facial Injuries | 1 | 2018 | 21 | 0.140 |
Why?
|
| Women's Health | 2 | 2016 | 150 | 0.140 |
Why?
|
| Program Evaluation | 2 | 2016 | 457 | 0.140 |
Why?
|
| Nose | 1 | 2018 | 105 | 0.130 |
Why?
|
| Young Adult | 3 | 2016 | 9912 | 0.130 |
Why?
|
| Postnatal Care | 1 | 2016 | 52 | 0.130 |
Why?
|
| Antibodies, Viral | 3 | 2020 | 1210 | 0.130 |
Why?
|
| Text Messaging | 1 | 2016 | 39 | 0.120 |
Why?
|
| Rotavirus Vaccines | 1 | 2016 | 73 | 0.120 |
Why?
|
| Infant | 10 | 2022 | 13181 | 0.110 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 473 | 0.110 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 45 | 0.110 |
Why?
|
| Female | 14 | 2022 | 71818 | 0.110 |
Why?
|
| United States | 4 | 2020 | 11752 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 1075 | 0.110 |
Why?
|
| Public Health | 1 | 2016 | 287 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 651 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2020 | 887 | 0.100 |
Why?
|
| Adult | 5 | 2016 | 31958 | 0.100 |
Why?
|
| Rotavirus | 1 | 2016 | 502 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 438 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 495 | 0.090 |
Why?
|
| Humans | 16 | 2025 | 134032 | 0.090 |
Why?
|
| Vaccines, Conjugate | 3 | 2017 | 83 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 717 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2017 | 697 | 0.080 |
Why?
|
| Pregnancy | 4 | 2016 | 7568 | 0.080 |
Why?
|
| Mother-Child Relations | 1 | 2010 | 79 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8599 | 0.080 |
Why?
|
| Weight Gain | 1 | 2010 | 412 | 0.070 |
Why?
|
| Male | 10 | 2022 | 66022 | 0.070 |
Why?
|
| Mothers | 1 | 2010 | 370 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 867 | 0.060 |
Why?
|
| Fever | 2 | 2020 | 312 | 0.060 |
Why?
|
| Ghana | 1 | 2025 | 25 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2022 | 14818 | 0.060 |
Why?
|
| Accreditation | 1 | 2025 | 93 | 0.060 |
Why?
|
| Adolescent | 3 | 2020 | 20581 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 17507 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2010 | 1717 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 757 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 820 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 1492 | 0.040 |
Why?
|
| Mumps | 1 | 2020 | 12 | 0.040 |
Why?
|
| Foster Home Care | 1 | 2020 | 20 | 0.040 |
Why?
|
| Rubella | 1 | 2020 | 24 | 0.040 |
Why?
|
| Government Regulation | 1 | 2020 | 43 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2016 | 13050 | 0.040 |
Why?
|
| Measles | 1 | 2020 | 44 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 250 | 0.040 |
Why?
|
| Exanthema | 1 | 2020 | 71 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2022 | 375 | 0.040 |
Why?
|
| Contusions | 1 | 2018 | 17 | 0.040 |
Why?
|
| Obesity | 1 | 2010 | 2444 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 14 | 0.030 |
Why?
|
| Mental Health | 1 | 2020 | 373 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2017 | 98 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2017 | 113 | 0.030 |
Why?
|
| Aged | 1 | 2015 | 21750 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2018 | 212 | 0.030 |
Why?
|
| Child | 3 | 2022 | 25816 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 420 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 407 | 0.030 |
Why?
|
| Middle Aged | 1 | 2015 | 29393 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 285 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1737 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 639 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1665 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1976 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 433 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 649 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 905 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 3228 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2195 | 0.020 |
Why?
|
| Child Development | 1 | 2010 | 286 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5206 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1338 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 3432 | 0.020 |
Why?
|
| Gestational Age | 1 | 2010 | 1227 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 2994 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 2683 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3660 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 11162 | 0.010 |
Why?
|